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Background: One of the main causes of mortality and morbidity following subarachnoid haemorrhage (SAH) is the
development of cerebral vasospasm, a frequent complication arising in the weeks after the initial bleeding. Despite
extensive research, to date no effective treatment of vasospasm exists. Prostacyclin is a potent vasodilator and
inhibitor of platelet aggregation. In vitro models have shown a relaxing effect of prostacyclin after induced
contraction in cerebral arteries, and a recent pilot trial showed a positive effect on cerebral vasospasm in a clinical
setting. No randomised, clinical trials have been conducted, investigating the possible pharmacodynamic effects of
prostacyclin on the human brain following SAH.
Methods: This trial is a single-centre, randomised, placebo-controlled, parallel group, blinded, clinical, pilot trial. A
total of 90 patients with SAH will be randomised to one of three intervention arms: epoprostenol 1 ng/kg/min,
epoprostenol 2 ng/kg/min or placebo in addition to standard treatment. Trial medication will start day 5 after SAH
and continue to day 10. The primary outcome measure is changes in regional cerebral blood flow from baseline in
the arterial territories of the anterior cerebral artery, medial cerebral artery and the posterior cerebral artery,
measured by CT perfusion scan. The secondary outcomes will be vasospasm measured by CT angiography,
ischaemic parameters measured by brain microdialysis, flow velocities in the medial cerebral artery, clinical
parameters and outcome (Glasgow Outcome Scale) at 3 months.
Trial registration: Clinicaltrials.gov NCT01447095.
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deficitBackground
Subarachnoid haemorrhage (SAH) accounts for only 5%
of strokes, but due to the poor prognosis and lower pa-
tient age than for patients with ischaemic stroke, the loss
of productive life years due to SAH approaches that for
ischaemic stroke and intracerebral haemorrhage [1].
One of the main causes of mortality and morbidity fol-
lowing SAH is the development of delayed ischaemic* Correspondence: rune333@gmail.com
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distribution, and reproduction in any mediumneurological deficit (DIND) [2]. DIND occurs in ap-
proximately 30% of all patients and often develops
within the first 2 weeks after the haemorrhage, with
maximum onset between days 4 and 10 [3,4]. The pre-
sumed cause of DIND is the development of cerebral
vasospasm (CV), which can be demonstrated by angiog-
raphy in 70% of patients following SAH [4]. However,
not all patients with angiographic vasospasm suffer
DIND and DIND can occur without evidence of arterial
narrowing [3]. Several mechanisms have been suggested
as additional causes of DIND, e.g. microthrombosis [5];tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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most important factor.
The pathophysiology behind the development of CV is
complex and remains poorly understood, but factors
related to the vascular endothelium and the smooth
muscle cell play a crucial role [6]. Several intervention
options, including HHH (hypertension, hypervolemia,
hemodilution), calcium antagonists, angioplasty, endothe-
lin-receptor antagonists and statins have been used to pre-
vent or treat vasospasm, but to date treatments with
convincing effects are lacking.
Prostacyclin (PGI2) is an endogenous substance
released from the vascular endothelium. It is a potent
vasodilator and inhibitor of leukocyte activation, platelet
aggregation and leukocyte-endothelial interactions [7]. A
reduced amount of prostacyclin has been found in cere-
bral vessels in monkeys following SAH, and an imbal-
ance in the prostacyclin-prostaglandin ratio has been
proposed as a cause of vasospasm [8,9].
In vitro studies have demonstrated a relaxing effect of
low-dose prostacyclin on cerebral vessels after induced
contraction [9-11], and animal studies have demon-
strated a positive effect of PGI2 on cerebral blood flow
in rats with traumatic brain injury [12,13].
A limited number of studies exist investigating the
possible effects of prostacyclin on cerebral vessels in a
clinical setting. A case report has described significant
recovery from segmental vasoconstriction in the brain
after administration of prostacyclin 0.9 ng/kg/min [14].
In a study of five patients with traumatic brain injury,
normalization of ischaemic parameters measured by
cerebral microdialysis was seen after administration of
low-dose prostacyclin (0.5-1 ng/kg/min) [15]. However,
a randomized, blinded trial of 48 patients with traumatic
brain injury was not able to reproduce this effect [16].
A recent pilot trial from 2009 investigated the effect of
low-dose prostacyclin on vasospasm following SAH. In
five patients with documented cerebral vasospasm, pros-
tacyclin 0.5 ng/kg/min was administered and flow veloci-
ties in the medial cerebral artery were subsequently
monitored by transcranial Doppler. In all patients, flow
velocities decreased markedly as an expression of the
resolution of vasospasm [17].
To date, no randomised, clinical trials have been con-
ducted investigating the possible pharmacodynamic
effects of prostacyclin on the vascular bed of the human
brain following SAH (search details in Table 1).
Although the use of prostacyclin in the treatment of
cerebrovascular disease so far has only been experimen-
tal, synthetic prostacyclin (epoprostenol) has been used
as a standard treatment for pulmonary hypertension for
years, in doses 2–20 times higher than doses used in this
trial. The side effects of these high doses are well known
and include the risk of hypotension due to vasodilationand the risk of bleeding. The experience using low-dose
prostacyclin in the treatment of neurovascular disease is
limited. In the above-mentioned trial of 48 patients with




This trial is a single-centre, randomised, placebo-
controlled, parallel group, blinded, clinical trial. The trial
is an explorative, pilot trial designed to investigate the
feasibility and possible effects of low-dose prostacyclin
on the primary outcome of regional blood flow and
vasospasm in the human brain following SAH.
The trial is being conducted at Rigshospitalet, Copen-
hagen University Hospital, Neurointensive Care Unit,
Denmark. The trial was approved by the Danish ethical
committee on human research (reference no. H-1-2011
-087), the Danish Medicines Agency (EudraCT 2011-
002798-5) and registered on www.clinical.trials.gov
(reference no. NCT01447095), and will be carried out in
compliance with the Declaration of Helsinki. The trial
will be reported in compliance with the CONSORT
statement (www.consort-statement.org).
A total of 90 patients will be randomized to one of
three intervention arms, flowchart in Figure 1. No in-
terim analysis will take place. In- and exclusion criteria
are listed in Table 2.
Patient enrolment and randomization
Patients with SAH admitted at our institution with a
significant amount of blood in the subarachnoid space
(Fisher grade 3 + 4) are potential candidates for the trial.
After informed consent, patients are randomized to
either a continuous infusion of epoprostenol 1 ng/kg/
min, or epoprostenol 2 ng/kg/min, or placebo (drug
solvent). Concealed allocation is achieved by randomisa-
tion and allocation by specially assigned nurses without
patient contact. Randomisation is done using a com-
puter-generated allocation list from www.randomization.
com, only accessible by the specially assigned nurses not
Table 2 In- and exclusion criteria
Inclusion criteria SAH verified by CT
Fisher grade 3 + 4
Aneurysm treated by surgical
clipping or endovascular coiling
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patient is included, the nurse is contacted by telephone
and the patient is subsequently randomised. The nurse
will then prepare the blinded trial medication according







Major complication during endovascular
procedure or surgery
Previous SAH
SAH on basis of PICA aneurysmEpoprostenol intervention
Trial medication will start on day 5 after SAH and
continue to day 10, as risk of vasospasm is at its highest
in this time interval. Trial medication is given in
addition to standard treatment and is administered as a
continuous intravenous infusion. Epoprostenol 500 mg
(Flolan R, GlaxoSmithKline) will be obtained and diluted
only with original solvent. Solutions of 5,000 ng/ml,
10,000 ng/ml and 0 ng/ml (pure solvent) will be pre-
pared. All solutions are colourless. Trial medications are
prepared in syringes, ready for infusion. The syringes are
marked with the patient ID, the same infusion rate for
all three solutions and date, and are then transported to
the neuro-intensive care unit. The infusion rate is deter-
mined by patient weight, according to the treatment
schedule. Only specially assigned nurses will handle theFigure 1 Flow diagram.trial medications until the transport to the neuro-
intensive care unit. Thereafter, the trial medication is
administered by the nursing staff on duty. Syringes will
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ious adverse events (hypotension, bleeding episodes or
anaphylaxis) occur, the trial medication will be stopped.
CT perfusion
Baseline CT perfusion (CTP) will be performed at day 3
(± 1 day) after SAH. CTP during the intervention is per-
formed at day 8 (± 1 day) after SAH. All scans are per-
formed on a Phillips Brilliance scanner.
The CTP scan covers a 4-cm area selected at the level
of the basal ganglia. CTP data acquisition consists of a
60-s series during intravenous administration of iodi-
nated contrast material (details in Table 3). All images
are stored on a database to be subjected to later blinded
analyses of the primary outcome measure.
Three regions of interests (ROIs) will be placed in each
hemisphere: The cortex of the arterial territory of the
anterior cerebral artery, the middle cerebral artery and
posterior cerebral artery. Regional cerebral blood flow
(rCBF) for each ROI is calculated using the deconvolu-
tion method (Philips Medical Systems, EBW workstation
v. 3.5).
CT angiography
Baseline CT angiography (CTA) will be performed rou-
tinely at admission. CTA during intervention is per-
formed day 8 ± 1 day after SAH, 10 min after CTP. A
caudocranial scanning direction is selected, covering the
entire brain down to 1 cm below the foramen magnum
(details in Table 3).
CTA raw data are reformatted in axial, sagittal and
coronal maximal intensity projection (MIP) images. MIP
images are reviewed by an experienced neuroradiologist
for vasospasm and qualified as absent, mild/moderate or
severe.
Brain microdialysis
Microdialysis catheters (CMA 70 10-mm membrane
length, 20-kd cutoff) are inserted into the white matter in
the arterial territory of the aneurysm-bearing artery.
The microdialysis catheters are perfused (Perfusion
Fluid, CMA Microdialysis) at a rate of 0.3 l/min, and the
perfusates are collected in capped microvials at 2-hTable 3 Scanning protocol for CT perfusion (CTP) and CT
angiography (CTA)
CTP CTA
Amount of contrast 40 ml 70 ml
Injection rate 4 ml/s 4 ml/s
Acquisition parameters 80 kVp and 110 mAs 120 kVp/190 mA
Section thickness 5 mm 0.67 mmintervals. The samples are analysed for glucose, pyruvate,
lactate and glycerol (ISCUS Microdialysis Analyzer). The
area under the curve is calculated for each substance
before, during and after intervention.
Follow-up
Three months after SAH, all patients will be contacted by
phone or are seen in our outpatient clinic. Clinical
outcome will be recorded using the Glasgow Outcome
Scale (GOS).
Outcome measures
Two types of regions of interest (ROIs) are considered
equally biological relevant and accordingly the two co-pri-
mary outcomes will focus on:
1) regions with decreased blood flow (<30 ml/100 g/
min) at baseline
2) regions with decreased blood flow during the
intervention (measured on day 8 ± 1 day).
Regions with normal regional cerebral blood flow
(rCBF) both at baseline and after the intervention period
will be considered to have normal regional blood flow
during and after the intervention period.
Thus, two separate analyses will be performed:
1. ROIs with decreased flow values at the baseline
scan: The mean rCBFs for these ROIs are calculated
for each patient. Thereafter, the mean values of the
corresponding ROIs on the intervention scan are
calculated. The averages of differences of these mean
values are compared between intervention groups
using analysis of covariance.
2. ROIs with decreased flow values at the intervention
scan: The mean rCBFs for these ROIs are calculated
for each patient. Thereafter, the mean values of the
corresponding ROIs at the baseline scan are
calculated. The averages of differences of these mean
values are then compared between intervention
groups using analysis of covariance.
Secondary outcome measures will be:
– Radiographic vasospasm measured by CT
angiography
– Microdialysis parameters (as described above)
– Occurrence of DIND as defined by Vergouwen et al.
[3]. Any occurrence of DIND will be recorded by
the physician on duty and verified by the
investigator on a daily basis.
– Mortality and morbidity (GOS) at 3 months
– Flow velocities in a. cerebri media measured with
transcranial Doppler
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Adverse reactions
Serious adverse reactions (SARs) and suspected unex-
pected serious adverse reactions (SUSARs) will be regis-
tered according to the protocol approved by the Danish
Medicines Agency (DMA). As all patients with SAH are
expected to experience events due to their critical
illness; only SARs and SUSARs will be reported to health
authorities in compliance with the national legislation.
Monitoring
This trial is monitored by The GCP unit at Copenhagen
University Hospital. As the intervention is a low-dose
epoprostenol infusion with low risk and the trial inclu-
sion period as well as the sample size are limited, no
data safety and monitoring committee has been estab-
lished in accordance with the protocol and the DMA.
Sample size estimation
Difference in changes of regional cerebral blood flow
day 8 (± 1 day) from baseline will be the two co-primary
outcome measures of the trial. Based on a type 1 error
risk of 2.5%, a type 2 error risk of 20% (a power of 80%),
a standard deviation of 25% and the possibility to detect
or reject a 20% difference in the change of average
regional CBF from baseline between the intervention
groups, 30 patients per intervention arm have to be
randomised.
Statistical analyses
Analysis of covariance will be performed for the primary
outcome measure to allow for individual levels at base-
line of the covariates age, previous neurological status
and the mean rCBF for ROIs affected at baseline to be
taken into account [18]. Ordinal logistic regression will
be performed for the effect on GOS pending the inter-
vention group using the proportional odds approach; the
model considers every possible way in which an ordinal
scale can be dichotomized, assuming that the odds ratio
for a better outcome versus a worse outcome is identical
wherever the scale is dichotomized. Each patient contri-
butes to the underlying analyses and we obtain an over-
all estimate of the shift in outcome across the GOS
called a “shift analysis [19]. Depending on the distribu-
tion of other continuous outcomes, an independent
samples t-test or log-transformed or Mann–Whitney U
test will be used as appropriate. Binary outcomes will be
compared using Fisher’s exact probability test; 95% con-
fidence limits will be calculated and P-values <0.025 for
both of the co-primary outcomes will be considered sta-
tistically significant, that is, a cumulated family-wiseerror risk of 0.05 at the most will be allowed if statistical
significance is declared.Discussion
One of the main challenges in evaluating possible effects
of a novel drug on cerebral vasospasm is the choice of
outcome measures. Mortality and morbidity are not suit-
able as primary endpoints of a pilot trial due to the
required sample size. Clinical parameters, transcranial
Doppler, CT angiography, digital subtraction angiog-
raphy, invasive monitoring and CT perfusion all have
their strengths and weaknesses. The ideal parameter
would be continuous, non-invasive, specific and easily
quantified, but such a parameter does not exist because
of the complex nature of vasospasm. Radiographic vaso-
spasm without clinical symptoms is frequent and clinical
symptoms (DIND) can be seen without evidence of
arterial narrowing. In this trial we have chosen cerebral
perfusion as the primary outcome measure as this seems
to be a possible surrogate outcome measure with high
biological relevance. However, the secondary outcome
measures in this explorative trial are also considered
important.
One could argue that in order to attempt to prevent
the development of vasospasm, intervention during the
entire period at risk (i.e. days 1–21) would be reasonable.
However, the logistics at our institution do not allow for
all patients to be monitored sufficiently for the entire
3-week period. Furthermore, CT perfusion scans must be
performed in the day time (and not on weekends) for
logistical reasons, and baseline values must be obtained
before the intervention is initiated. Consequently, we have
chosen to test the interventions in the period with the
maximum risk of vasospasm (days 5–10).
The maximum dose of 2 ng/kg/min in the present trial is
relatively low compared to some other clinical indications
for the use of prostacyclin such as pulmonary hypertension,
where doses of 20 ng/kg/min or more are used. In animal
experiments it has been shown, however, that doses in the
range of 0.5-2 ng/kg/min have physiological effects by im-
proving microcirculation and reducing microvascular per-
meability in the brain, skeletal muscle and intestines
[12,14,15,20,21]. This has also been shown in the human
brain [14,15,20]. A previous study suggesting beneficial
effects on vasospasm with prostacyclin used doses in the
range of 0.5-1 ng/kg/min [17]. These doses also fulfil the
theoretical rationale behind the administration of prosta-
cyclin to patients with SAH, to compensate for the
decreased endogenous production. A dose of 1–2 ng/kg/
min may therefore be effective and at the same time avoid
the well-known adverse effects due to higher doses, such as
hypotension, bleeding, abdominal pain and headache, some
of which are unacceptable for our trial patients.
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